Routine RTA compliance certificate filed for July to September 2026 quarter

Compliance View source PDF Explain this filing

SUPRIYA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.4%Reaction day

₹861.00

prior close

₹862.75

announcement price

After-mkt

timing

Nifty Microcap 250market+0.2%+2.2% vs market

Pharmaceuticals peers, median of 168sector-0.3%+2.7% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 2.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.9

10m

-1.9

15m

-2.1

30m

-2.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.4+0.2+2.2-0.3+2.7

Next day

+1.0+0.9+0.2-0.3+1.4

+1.3-0.8+2.1-1.2+2.5

+2.9-0.1+3.0-1.0+3.9

+1.3-1.7+3.1-2.6+3.9

-1.4-4.3+2.9-4.0+2.6

-5.7-7.5+1.7-6.5+0.8

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 168Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Supriya Lifescience has submitted a quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended September 30, 2026. The certificate was issued by MUFG Intime India, the company Registrar and Share Transfer Agent, confirming that all share dematerialisation requests received during the quarter were properly processed, confirmed, and listed on the stock exchanges. Original certificates were mutilated and cancelled as per SEBI rules. This is a routine procedural regulatory filing.

Likely market impact

Routine compliance filing. No material impact on shareholders or stock price.